{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:36:29Z","timestamp":1794472589790,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jocn.2025.111745","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T17:45:54Z","timestamp":1762710354000},"page":"111745","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dual antiplatelet therapy guided by CYP2C19 polymorphism after intracranial or extracranial stenting: A single-center retrospective cohort study"],"prefix":"10.1016","volume":"143","author":[{"given":"Fan","family":"qingyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhang","family":"Guilian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Mengchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fangcun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2025.111745_b0005","unstructured":"Chinese Society of Neurology, Cerebrovascular Disease Group. Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack 2021. Chin J Neurol. 2021;54(12):1239-1254."},{"issue":"5","key":"10.1016\/j.jocn.2025.111745_b0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 Update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jocn.2025.111745_b0015","article-title":"CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel","volume":"22","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.jocn.2025.111745_b0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1055\/s-0040-1709520","article-title":"Cilostazol for Chinese patients with aspirin intolerance after coronary drug-eluting stent implantation","volume":"120","author":"Dai","year":"2020","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jocn.2025.111745_b0025","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/cpt.3026","article-title":"PTRG-DES consortium investigators. High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention","volume":"114","author":"Kim","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.jocn.2025.111745_b0030","first-page":"651","article-title":"Efficacy and safety of genotype-guided antiplatelet therapy versus standard treatment in 4,604 patients with CAD after PCI: a meta-analysis of randomized controlled trials","volume":"75","author":"Liu","year":"2020","journal-title":"Pharmazie"},{"issue":"27","key":"10.1016\/j.jocn.2025.111745_b0035","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jocn.2025.111745_b0040","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.3390\/jcm9123907","article-title":"Effectiveness of Platelet function analysis-guided aspirin and\/or clopidogrel therapy in preventing secondary stroke: A systematic review and meta-analysis","volume":"9","author":"Yan","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jocn.2025.111745_b0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/STROKEAHA.122.039900","article-title":"Dual antiplatelet therapy with cilostazol for secondary prevention in lacunar stroke: Subanalysis of the CSPS.com trial","volume":"54","author":"Nishiyama","year":"2023","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.jocn.2025.111745_b0050","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(19)30148-6","article-title":"CSPS.com Trial Investigators. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: A multicentre, open-label, randomised controlled trial","volume":"18","author":"Toyoda","year":"2019","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111745_b0055","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70258","article-title":"Understanding drug interactions in antiplatelet therapy for atherosclerotic vascular disease: A systematic review","volume":"31","author":"Huang","year":"2025","journal-title":"CNS Neurosci Ther"},{"issue":"9749","key":"10.1016\/j.jocn.2025.111745_b0060","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jocn.2025.111745_b0065","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","article-title":"Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome \u2013 randomized, double-blind, phase III PHILO study","volume":"79","author":"Goto","year":"2015","journal-title":"Circ J"},{"issue":"3","key":"10.1016\/j.jocn.2025.111745_b0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jocn.2025.111745_b0075","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.116.025250","article-title":"Feigin VL; NESS-China investigators. Prevalence, incidence, and mortality of stroke in china: results from a nationwide population-based survey of 480\u2009687 adults","volume":"135","author":"Wang","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jocn.2025.111745_b0080","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamaneurol.2021.4804","article-title":"Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: A randomized clinical trial","volume":"79","author":"Jia","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jocn.2025.111745_b0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.thromres.2022.09.019","article-title":"Role of thrombin to non-physiological shear stress induced platelet activation and function alternation","volume":"219","author":"Sun","year":"2022","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.jocn.2025.111745_b0090","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.5551\/jat.63632","article-title":"Comparison of cilostazol versus clopidogrel in addition to aspirin in patients with ischemic stroke who underwent intracranial or extracranial artery stent implantation","volume":"30","author":"Liu","year":"2023","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"10.1016\/j.jocn.2025.111745_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104400","article-title":"Coronary artery disease in patients with ischemic stroke and TIA","volume":"28","author":"Bhatia","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"4","key":"10.1016\/j.jocn.2025.111745_b0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.4103\/0028-3886.325337","article-title":"Clinical relevance of coronary artery disease in acute ischemic stroke","volume":"69","author":"Arboix","year":"2021","journal-title":"Neurol India"},{"issue":"5","key":"10.1016\/j.jocn.2025.111745_b0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jamaneurol.2022.0048","article-title":"Evaluating Rates of recurrent ischemic stroke among young adults with embolic stroke of undetermined source: The young ESUS longitudinal cohort study","volume":"79","author":"Perera","year":"2022","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.jocn.2025.111745_b0110","first-page":"1580","article-title":"Dual antiplatelet therapy: A concise review for clinicians","volume":"13","author":"Virk","year":"2023","journal-title":"Life (Basel)"},{"issue":"63","key":"10.1016\/j.jocn.2025.111745_b0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-pharmtox-051921-092701","article-title":"Pharmacogenetics of Antiplatelet Therapy","volume":"20","author":"Castrichini","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"15","key":"10.1016\/j.jocn.2025.111745_b0120","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jacc.2023.07.025","article-title":"Antithrombotic Therapy for primary and secondary prevention of ischemic stroke: JACC state-of-the-art review","volume":"82","author":"Greco","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jocn.2025.111745_b0125","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3390\/jcm10081721","article-title":"Oral antiplatelet therapy for secondary prevention of non-cardioembolic ischemic cerebrovascular events","volume":"10","author":"De Luca","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.jocn.2025.111745_b0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000530602","article-title":"Safety and efficacy of ticagrelor versus clopidogrel in east asian patients with acute coronary syndrome undergoing percutaneous coronary intervention treated with dual antiplatelet therapy: A meta-analysis of randomized controlled trials","volume":"148","author":"Li","year":"2023","journal-title":"Cardiology"},{"issue":"6","key":"10.1016\/j.jocn.2025.111745_b0135","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s10557-023-07534-0","article-title":"Impact of CYP2C19 genotype on efficacy and safety of clopidogrel-based antiplatelet therapy in stroke or transient ischemic attack patients: An updated systematic review and meta-analysis of non-East Asian Studies","volume":"38","author":"Cargnin","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"issue":"13","key":"10.1016\/j.jocn.2025.111745_b0140","article-title":"Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis","volume":"10","author":"Luo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.jocn.2025.111745_b0145","article-title":"A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients","volume":"24","author":"Ai","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.jocn.2025.111745_b0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3349\/ymj.2022.63.5.413","article-title":"PTRG-DES consortium investigators. Platelet function and genotype after DES implantation in East Asian Patients: Rationale and characteristics of the PTRG-DES consortium","volume":"63","author":"Her","year":"2022","journal-title":"Yonsei Med J"},{"issue":"4","key":"10.1016\/j.jocn.2025.111745_b0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/svn-2022-001720","article-title":"Roles of light transmission aggregometry and CYP2C19 genotype in predicting ischaemic complications during interventional therapy for intracranial aneurysms","volume":"8","author":"Zhou","year":"2023","journal-title":"Stroke Vasc Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825007180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825007180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:19:01Z","timestamp":1769296741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825007180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"alternative-id":["S0967586825007180"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111745","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual antiplatelet therapy guided by CYP2C19 polymorphism after intracranial or extracranial stenting: A single-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111745","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111745"}}